A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer.
| dc.contributor.author | Gupta, Nirmal K | |
| dc.contributor.author | Pointon, R C S | |
| dc.contributor.author | Wilkinson, Peter M | |
| dc.date.accessioned | 2010-10-20T10:38:54Z | |
| dc.date.available | 2010-10-20T10:38:54Z | |
| dc.date.issued | 1987-11 | |
| dc.identifier.citation | A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. 1987, 38 (6):575-81 Clin Radiol | en |
| dc.identifier.issn | 0009-9260 | |
| dc.identifier.pmid | 3121233 | |
| dc.identifier.doi | 10.1016/S0009-9260(87)80327-6 | |
| dc.identifier.uri | http://hdl.handle.net/10541/113540 | |
| dc.description.abstract | Three hundred and thirteen patients with squamous cell cancer of the head and neck were entered in a randomised clinical trial to determine whether the addition of methotrexate during the course of irradiation improved the rate of primary control and subsequent survival. The overall primary control (P = 0.016) and survival (P = 0.075) for the patients receiving methotrexate was better than the patients treated by radiotherapy alone. The improvement in primary control (P = 0.0019) and survival (P = 0.0089) in patients with oropharyngeal cancers who had methotrexate in addition to radiotherapy is statistically significant. The treatment was well tolerated and there has been no increase of late morbidity. | |
| dc.language.iso | en | en |
| dc.subject | Head and Neck Cancer | en |
| dc.subject.mesh | Carcinoma, Squamous Cell | |
| dc.subject.mesh | Clinical Trials as Topic | |
| dc.subject.mesh | Combined Modality Therapy | |
| dc.subject.mesh | Head and Neck Neoplasms | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Methotrexate | |
| dc.subject.mesh | Radiotherapy, High-Energy | |
| dc.subject.mesh | Random Allocation | |
| dc.title | A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Radiotherapy, Christie Hospital and Holt Radium Institute, Manchester. | en |
| dc.identifier.journal | Clinical Radiology | en |
| html.description.abstract | Three hundred and thirteen patients with squamous cell cancer of the head and neck were entered in a randomised clinical trial to determine whether the addition of methotrexate during the course of irradiation improved the rate of primary control and subsequent survival. The overall primary control (P = 0.016) and survival (P = 0.075) for the patients receiving methotrexate was better than the patients treated by radiotherapy alone. The improvement in primary control (P = 0.0019) and survival (P = 0.0089) in patients with oropharyngeal cancers who had methotrexate in addition to radiotherapy is statistically significant. The treatment was well tolerated and there has been no increase of late morbidity. |